Key result
ACE2 mutations and expression correlate with tumor prognosis and reduced cancer-associated fibroblast immune infiltration.
Why the study?
Variations of ACE2 play an irreplaceable role in the renin-angiotensin system and are regarded as key factors in human diseases such as cardiovascular disease, novel coronavirus pneumonia, and tumors.
May inform cardio-oncology biomarker research; leaves open whether ACE2 targeting alters tumor outcomes or cardiovascular risk.
ACE2, a member of the angiotensin converting enzyme family, plays an irreplaceable role in the renin-angiotensin system. And the variations of ACE2 are regarded as the key factor to human diseases such as the novel coronavirus pneumonia, cardiovascular disease, and tumors. Here, we summarized the mutation, expression, modification and function of the human ACE2 based on comprehensive bioinformatics analysis. Especially, the relationship between ACE2 expression and diseases, especially tumor was further discussed. ACE2 is highly conserved in different genera and families. We explored the correlation between ACE2 and disease based on the datasets of GCBI and GEO (Gene expression omnibus), and found the expression of ACE2 is related to heart failure. High prevalence of ACE2 mutations is observed in diffuse large B-cell lymphoma, uterine carcinosarcoma (UCS), and stomach adenocarcinoma (STAD). We first identified that highly expressed of ACE2 was linked to poor prognosis of overall survival for tumors of brain lower grade glioma (LGG). Specially, the expression level of ACE2 in kidney-related tumor tissues is much higher than that of normal kidney tissues. ACE2 is negatively correlated with the infiltration level of cancer-associated fibroblasts in most kinds of cancers, such as uterine corpus endometrial carcinoma (UCEC), esophageal carcinoma (ESCA), ovarian serous cystadenocarcinoma (OV) and kidney renal clear cell carcinoma (KIRC); positively correlation in testicular germ cell tumors (TGCT). The different phosphorylation sites of ACE2 were analyzed in CPTAC dataset, and the DNA methylation of ACE2 in colon adenocarcinoma (COAD), kidney renal papillary cell carcinoma (KIRP), and rectum adenocarcinoma (READ) was lower than that of normal control by using SMART database. Moreover, we summarized the interaction proteins and targeted miRNAs of ACE2 through bioinformatics. Then we found the endocrine process and the regulation of systemic arterial blood pressure were involved in the functional mechanisms of ACE2 by using KEGG and GO analysis. Our study offers a relatively comprehensive understanding of ACE2.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) studied Cancer and ACE2-related diseases (n=10,953). ACE2 expression and mutations vs. Normal tissues or low ACE2 expression was evaluated on Correlation of ACE2 expression and mutations with tumor prognosis and immune infiltration. ACE2 mutations are highly prevalent in certain tumors, and its expression correlates with tumor prognosis and negatively correlates with immune infiltration of cancer-associated fibroblasts in most cancers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: